xB3-IL-1RA(xB3-IL-1RA) - 药物靶点：IL1R1_专利_临床

概要

基本信息

药物类型

融合蛋白

别名

IL-1 receptor antagonist (bioasis Technologies)、XB3-IL-1RA

靶点

IL1R1

作用方式

拮抗剂

作用机制

IL1R1拮抗剂(白细胞介素-1受体拮抗剂)

治疗领域

免疫系统疾病神经系统疾病内分泌与代谢疾病+ [1]

在研适应症-

非在研适应症

桥本脑炎多发性硬化症神经痛

原研机构

biOasis Technologies, Inc.

在研机构-

非在研机构

biOasis Technologies, Inc.

权益机构-

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 xB3-IL-1RA 相关的临床结果

登录后查看更多信息

100 项与 xB3-IL-1RA 相关的转化医学

登录后查看更多信息

100 项与 xB3-IL-1RA 相关的专利（医药）

登录后查看更多信息

189

项与 xB3-IL-1RA 相关的文献（医药）

2025-08-01·PEDIATRIC BLOOD & CANCER

Efficacy of High‐Dose Intravenous Anakinra in Pediatric TAFRO Syndrome: Report of Two Cases and Literature Review

Review

作者: Natoli, Valentina ; Rosina, Silvia ; Matucci‐Cerinic, Caterina ; Palmeri, Serena ; Vellone, Valerio Gaetano ; Sorrentino, Stefania ; Caorsi, Roberta ; Ferro, Jacopo ; Papa, Riccardo ; Volpi, Stefano ; Gattorno, Marco

ABSTRACT:

TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly) syndrome is a rare, life‐threatening inflammatory condition linked to infections, neoplasms, and idiopathic multicentric Castleman disease. Interleukin (IL)‐6 inhibitors are the primary treatment, but refractory cases require alternatives. This study reports the first two pediatric TAFRO cases successfully treated with anakinra, an IL‐1 receptor antagonist. Both patients had severe, rapidly progressing disease with multiorgan involvement. Anakinra, combined with corticosteroids, led to significant improvement and remission. We provide a literature review of pediatric TAFRO, confirming its rarity and the partial efficacy of IL‐6 inhibitors in many cases.

2025-04-01·OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Comparison of IL‐1 Receptor Antagonist and Dexamethasone in Noise‐Induced Hearing Loss: Animal Model

Article

作者: Kamişli, Gurbet İ. Ş. ; Yiğman, Zeynep ; Tufan, Abdurrahman ; Billur, Deniz ; Gündüz, Bülent ; Yaşar, Nagihan G. ; Karamert, Recep

Abstract:

Objective:

This study aimed to attenuate cochlear inflammation following noise‐induced hearing loss by targeting IL‐1. We evaluated the effectiveness of IL‐1 inhibition through auditory and histological assessments in an animal model.

Study design:

Experimental animal study.

Setting:

Gazi University Faculty of Medicine, Ankara, Turkey.

Methods:

Twenty‐four rats were randomly assigned into 3 groups: Anakinra, dexamethasone, and control groups. All animals were exposed to broadband noise (110 dB SPL, 8 hours), auditory brainstem response (ABR) tests were conducted before noise exposure, immediately after, and on Day 14. Anakinra, dexamethasone, and saline were administered intraperitoneally, cochlear tissues were harvested for histological and immunohistochemical evaluation.

Results:

On Day 14, ABR thresholds in Anakinra group were better than the control group across all frequencies, with a significant difference observed at 8 kHz (P = .036). The mean number of OHC was significantly higher in Anakinra group compared to the control group (P < .05). The mean number of IHC in the Anakinra group was greater than in the dexamethasone group. IL‐1β immunopositivity in the stria vascularis and spiral ganglia was significantly higher in Anakinra group compared to dexamethasone group (P = .022 and P = .013, respectively). TNF‐α immunopositivity in the stria vascularis and spiral ganglia was significantly greater in control group than in Anakinra group (P = .037 and P = .01, respectively).

Conclusion:

The comparable efficacy of Anakinra and dexamethasone in both histological and auditory assessments suggests that Anakinra may serve as a promising therapeutic option for noise‐induced hearing loss.

2025-03-01·ARTIFICIAL ORGANS

IL‐1 receptor antagonist anakinra downregulates inflammatory cytokines during renal normothermic machine perfusion: Preliminary results

Article

作者: Hosgood, Sarah A. ; Nicholson, Michael L. ; Walker, Alex ; Moore, Tom

Abstract:

Background:

The interleukin 1 (IL‐1) cytokine group plays a key role in sterile inflammation and may be an important target for transplant‐related renal injury. This study examined the effects of anakinra, a non‐specific IL‐1 receptor antagonist, administered during normothermic machine perfusion (NMP) of porcine kidneys.

Method:

Paired porcine kidneys (n = 5 pairs) underwent 15 min of warm ischemia plus 2 h of static cold storage in ice. Kidneys were then perfused with autologous whole blood using an ex vivo NMP platform. Kidneys were randomly allocated to receive anakinra or vehicle administered at the start of NMP. Cortical biopsies were collected at baseline before ischemic injury and at the end of NMP. Functional parameters were recorded and calculated, and inflammatory markers were measured by qPCR and ELISA techniques.

Results:

During NMP, there were no statistically significant differences in renal blood flow, urine output, creatinine clearance or fractional excretion of sodium in the anakinra and control groups. The administration of anakinra significantly downregulated transcriptional expression of IL‐6, Fas ligand and intercellular adhesion molecule 1 (p = 0.029, 0.029, 0.028, respectively).

Conclusion:

Anakinra, an IL‐1 receptor blocker, successfully attenuated the downstream inflammatory and immune‐mediated response within the kidney during NMP.

100 项与 xB3-IL-1RA 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
桥本脑炎	临床前	美国	biOasis Technologies, Inc.	-
多发性硬化症	临床前	美国	biOasis Technologies, Inc.	-
神经痛	临床前	美国	biOasis Technologies, Inc.	-